Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2015
Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.
Open access · bronzeAbstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
6.2field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Cardiovascular Toxicities with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of 77 Randomized Controlled Trials.Clinical drug investigation · 2018Pooled it
- The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials.Lung cancer (Amsterdam, Netherlands) · 2016Pooled it
- Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015Trial
- Results of a phase I, open-label, randomized, crossover study evaluating the effects of linifanib on QTc intervals in patients with solid tumors.Cancer chemotherapy and pharmacology · 2014Trial
- PHDs-seq: a large-scale phenotypic screening method for drug discovery through parallel multi-readout quantification.Cell regeneration (London, England) · 2023Article
- Dual-Bioorthogonal Catalysis by a Palladium Peptide Complex.Journal of medicinal chemistry · 2023Article
- Anti-Angiogenic Therapy inInternational journal of molecular sciences · 2022Review
- [Research Progress of Small Molecule Anti-angiogenic Drugs in Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2021Review
- MKL1/miR-5100/CAAP1 loop regulates autophagy and apoptosis in gastric cancer cells.Neoplasia (New York, N.Y.) · 2020Article
- VEGFR-TKIs combined with chemotherapy for advanced non-small cell lung cancer: A systematic review.Journal of Cancer · 2019Article
- Review
- Use of multitarget tyrosine kinase inhibitors to attenuate platelet-derived growth factor signalling in lung disease.European respiratory review : an official journal of the European Respiratory Society · 2017Review
- Review
- Patient subgroup identification for clinical drug development.Statistics in medicine · 2017Article
- Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer.Translational lung cancer research · 2016Review
- Anti-vascular endothelial growth factor therapies at the crossroads: linifanib for non-small cell lung cancer.Translational lung cancer research · 2016Article
- Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).Translational lung cancer research · 2015Review
- Delineation of gastric cancer subtypes by co-regulated expression of receptor tyrosine kinases and chemosensitivity genes.American journal of translational research · 2015Article
- Therapeutic options targeting angiogenesis in nonsmall cell lung cancer.European respiratory review : an official journal of the European Respiratory Society · 2014Review
- Non-small-cell lung cancer: molecular targeted therapy and personalized medicine - drug resistance, mechanisms, and strategies.Pharmacogenomics and personalized medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 2 institutions in 1 country.
Suresh S RamalingamSuresh S. Ramalingam and Taofeek K. Owonikoko, Winship Cancer Institute of Emory University, Atlanta, GA; Mikhail Shtivelband, Ironwood Cancer and Research Centers, Chandler, AZ; Ross A. Soo, National University Cancer Institute, National University Health System, Singapore, Singapore; Carlos H. Barrios, Pontifícia Universidade Católica do Rio Grande do Sul School of Medicine, Porto Alegre; José G.M. Segalla, Hospital Amaral Carvalho, Jau; Jose R. Pereira, Instituto Brasileiro de Cancerologia Toracica, Sao Paulo, Brazil; Anatoly Makhson, Moscow City Oncology Hospital No. 62; Vera A. Gorbunova, N.N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia; Kenneth B. Pittman, The Queen Elizabeth Hospital, Woodville, South Australia, Australia; Petr Kolman, Hospital Kyjov, Kyjov, Czech Republic; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing, MI; Chandra P. Belani, Penn State Hershey Cancer Institute, Hershey; Rita Axelrod, Thomas Jefferson University Hospital, Philadelphia, PA; Qin Qin, Jiang Qian, Evelyn M. McKeegan, Viswanath Devanarayan, Mark D. McKee, Justin L. Ricker, and Dawn M. Carlson, AbbVie, North Chicago, IL. suresh.ramalingam@emory.edu.
Mikhail ShtivelbandSuresh S. Ramalingam and Taofeek K. Owonikoko, Winship Cancer Institute of Emory University, Atlanta, GA; Mikhail Shtivelband, Ironwood Cancer and Research Centers, Chandler, AZ; Ross A. Soo, National University Cancer Institute, National University Health System, Singapore, Singapore; Carlos H. Barrios, Pontifícia Universidade Católica do Rio Grande do Sul School of Medicine, Porto Alegre; José G.M. Segalla, Hospital Amaral Carvalho, Jau; Jose R. Pereira, Instituto Brasileiro de Cancerologia Toracica, Sao Paulo, Brazil; Anatoly Makhson, Moscow City Oncology Hospital No. 62; Vera A. Gorbunova, N.N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia; Kenneth B. Pittman, The Queen Elizabeth Hospital, Woodville, South Australia, Australia; Petr Kolman, Hospital Kyjov, Kyjov, Czech Republic; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing, MI; Chandra P. Belani, Penn State Hershey Cancer Institute, Hershey; Rita Axelrod, Thomas Jefferson University Hospital, Philadelphia, PA; Qin Qin, Jiang Qian, Evelyn M. McKeegan, Viswanath Devanarayan, Mark D. McKee, Justin L. Ricker, and Dawn M. Carlson, AbbVie, North Chicago, IL.
Ross A SooSuresh S. Ramalingam and Taofeek K. Owonikoko, Winship Cancer Institute of Emory University, Atlanta, GA; Mikhail Shtivelband, Ironwood Cancer and Research Centers, Chandler, AZ; Ross A. Soo, National University Cancer Institute, National University Health System, Singapore, Singapore; Carlos H. Barrios, Pontifícia Universidade Católica do Rio Grande do Sul School of Medicine, Porto Alegre; José G.M. Segalla, Hospital Amaral Carvalho, Jau; Jose R. Pereira, Instituto Brasileiro de Cancerologia Toracica, Sao Paulo, Brazil; Anatoly Makhson, Moscow City Oncology Hospital No. 62; Vera A. Gorbunova, N.N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia; Kenneth B. Pittman, The Queen Elizabeth Hospital, Woodville, South Australia, Australia; Petr Kolman, Hospital Kyjov, Kyjov, Czech Republic; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing, MI; Chandra P. Belani, Penn State Hershey Cancer Institute, Hershey; Rita Axelrod, Thomas Jefferson University Hospital, Philadelphia, PA; Qin Qin, Jiang Qian, Evelyn M. McKeegan, Viswanath Devanarayan, Mark D. McKee, Justin L. Ricker, and Dawn M. Carlson, AbbVie, North Chicago, IL.
Carlos H BarriosSuresh S. Ramalingam and Taofeek K. Owonikoko, Winship Cancer Institute of Emory University, Atlanta, GA; Mikhail Shtivelband, Ironwood Cancer and Research Centers, Chandler, AZ; Ross A. Soo, National University Cancer Institute, National University Health System, Singapore, Singapore; Carlos H. Barrios, Pontifícia Universidade Católica do Rio Grande do Sul School of Medicine, Porto Alegre; José G.M. Segalla, Hospital Amaral Carvalho, Jau; Jose R. Pereira, Instituto Brasileiro de Cancerologia Toracica, Sao Paulo, Brazil; Anatoly Makhson, Moscow City Oncology Hospital No. 62; Vera A. Gorbunova, N.N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia; Kenneth B. Pittman, The Queen Elizabeth Hospital, Woodville, South Australia, Australia; Petr Kolman, Hospital Kyjov, Kyjov, Czech Republic; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing, MI; Chandra P. Belani, Penn State Hershey Cancer Institute, Hershey; Rita Axelrod, Thomas Jefferson University Hospital, Philadelphia, PA; Qin Qin, Jiang Qian, Evelyn M. McKeegan, Viswanath Devanarayan, Mark D. McKee, Justin L. Ricker, and Dawn M. Carlson, AbbVie, North Chicago, IL.
Anatoly MakhsonSuresh S. Ramalingam and Taofeek K. Owonikoko, Winship Cancer Institute of Emory University, Atlanta, GA; Mikhail Shtivelband, Ironwood Cancer and Research Centers, Chandler, AZ; Ross A. Soo, National University Cancer Institute, National University Health System, Singapore, Singapore; Carlos H. Barrios, Pontifícia Universidade Católica do Rio Grande do Sul School of Medicine, Porto Alegre; José G.M. Segalla, Hospital Amaral Carvalho, Jau; Jose R. Pereira, Instituto Brasileiro de Cancerologia Toracica, Sao Paulo, Brazil; Anatoly Makhson, Moscow City Oncology Hospital No. 62; Vera A. Gorbunova, N.N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia; Kenneth B. Pittman, The Queen Elizabeth Hospital, Woodville, South Australia, Australia; Petr Kolman, Hospital Kyjov, Kyjov, Czech Republic; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing, MI; Chandra P. Belani, Penn State Hershey Cancer Institute, Hershey; Rita Axelrod, Thomas Jefferson University Hospital, Philadelphia, PA; Qin Qin, Jiang Qian, Evelyn M. McKeegan, Viswanath Devanarayan, Mark D. McKee, Justin L. Ricker, and Dawn M. Carlson, AbbVie, North Chicago, IL.
José G M SegallaSuresh S. Ramalingam and Taofeek K. Owonikoko, Winship Cancer Institute of Emory University, Atlanta, GA; Mikhail Shtivelband, Ironwood Cancer and Research Centers, Chandler, AZ; Ross A. Soo, National University Cancer Institute, National University Health System, Singapore, Singapore; Carlos H. Barrios, Pontifícia Universidade Católica do Rio Grande do Sul School of Medicine, Porto Alegre; José G.M. Segalla, Hospital Amaral Carvalho, Jau; Jose R. Pereira, Instituto Brasileiro de Cancerologia Toracica, Sao Paulo, Brazil; Anatoly Makhson, Moscow City Oncology Hospital No. 62; Vera A. Gorbunova, N.N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia; Kenneth B. Pittman, The Queen Elizabeth Hospital, Woodville, South Australia, Australia; Petr Kolman, Hospital Kyjov, Kyjov, Czech Republic; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing, MI; Chandra P. Belani, Penn State Hershey Cancer Institute, Hershey; Rita Axelrod, Thomas Jefferson University Hospital, Philadelphia, PA; Qin Qin, Jiang Qian, Evelyn M. McKeegan, Viswanath Devanarayan, Mark D. McKee, Justin L. Ricker, and Dawn M. Carlson, AbbVie, North Chicago, IL.
Kenneth B PittmanSuresh S. Ramalingam and Taofeek K. Owonikoko, Winship Cancer Institute of Emory University, Atlanta, GA; Mikhail Shtivelband, Ironwood Cancer and Research Centers, Chandler, AZ; Ross A. Soo, National University Cancer Institute, National University Health System, Singapore, Singapore; Carlos H. Barrios, Pontifícia Universidade Católica do Rio Grande do Sul School of Medicine, Porto Alegre; José G.M. Segalla, Hospital Amaral Carvalho, Jau; Jose R. Pereira, Instituto Brasileiro de Cancerologia Toracica, Sao Paulo, Brazil; Anatoly Makhson, Moscow City Oncology Hospital No. 62; Vera A. Gorbunova, N.N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia; Kenneth B. Pittman, The Queen Elizabeth Hospital, Woodville, South Australia, Australia; Petr Kolman, Hospital Kyjov, Kyjov, Czech Republic; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing, MI; Chandra P. Belani, Penn State Hershey Cancer Institute, Hershey; Rita Axelrod, Thomas Jefferson University Hospital, Philadelphia, PA; Qin Qin, Jiang Qian, Evelyn M. McKeegan, Viswanath Devanarayan, Mark D. McKee, Justin L. Ricker, and Dawn M. Carlson, AbbVie, North Chicago, IL.
Petr KolmanSuresh S. Ramalingam and Taofeek K. Owonikoko, Winship Cancer Institute of Emory University, Atlanta, GA; Mikhail Shtivelband, Ironwood Cancer and Research Centers, Chandler, AZ; Ross A. Soo, National University Cancer Institute, National University Health System, Singapore, Singapore; Carlos H. Barrios, Pontifícia Universidade Católica do Rio Grande do Sul School of Medicine, Porto Alegre; José G.M. Segalla, Hospital Amaral Carvalho, Jau; Jose R. Pereira, Instituto Brasileiro de Cancerologia Toracica, Sao Paulo, Brazil; Anatoly Makhson, Moscow City Oncology Hospital No. 62; Vera A. Gorbunova, N.N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia; Kenneth B. Pittman, The Queen Elizabeth Hospital, Woodville, South Australia, Australia; Petr Kolman, Hospital Kyjov, Kyjov, Czech Republic; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing, MI; Chandra P. Belani, Penn State Hershey Cancer Institute, Hershey; Rita Axelrod, Thomas Jefferson University Hospital, Philadelphia, PA; Qin Qin, Jiang Qian, Evelyn M. McKeegan, Viswanath Devanarayan, Mark D. McKee, Justin L. Ricker, and Dawn M. Carlson, AbbVie, North Chicago, IL.
Jose R PereiraSuresh S. Ramalingam and Taofeek K. Owonikoko, Winship Cancer Institute of Emory University, Atlanta, GA; Mikhail Shtivelband, Ironwood Cancer and Research Centers, Chandler, AZ; Ross A. Soo, National University Cancer Institute, National University Health System, Singapore, Singapore; Carlos H. Barrios, Pontifícia Universidade Católica do Rio Grande do Sul School of Medicine, Porto Alegre; José G.M. Segalla, Hospital Amaral Carvalho, Jau; Jose R. Pereira, Instituto Brasileiro de Cancerologia Toracica, Sao Paulo, Brazil; Anatoly Makhson, Moscow City Oncology Hospital No. 62; Vera A. Gorbunova, N.N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia; Kenneth B. Pittman, The Queen Elizabeth Hospital, Woodville, South Australia, Australia; Petr Kolman, Hospital Kyjov, Kyjov, Czech Republic; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing, MI; Chandra P. Belani, Penn State Hershey Cancer Institute, Hershey; Rita Axelrod, Thomas Jefferson University Hospital, Philadelphia, PA; Qin Qin, Jiang Qian, Evelyn M. McKeegan, Viswanath Devanarayan, Mark D. McKee, Justin L. Ricker, and Dawn M. Carlson, AbbVie, North Chicago, IL.
Gordan SrkalovicSuresh S. Ramalingam and Taofeek K. Owonikoko, Winship Cancer Institute of Emory University, Atlanta, GA; Mikhail Shtivelband, Ironwood Cancer and Research Centers, Chandler, AZ; Ross A. Soo, National University Cancer Institute, National University Health System, Singapore, Singapore; Carlos H. Barrios, Pontifícia Universidade Católica do Rio Grande do Sul School of Medicine, Porto Alegre; José G.M. Segalla, Hospital Amaral Carvalho, Jau; Jose R. Pereira, Instituto Brasileiro de Cancerologia Toracica, Sao Paulo, Brazil; Anatoly Makhson, Moscow City Oncology Hospital No. 62; Vera A. Gorbunova, N.N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia; Kenneth B. Pittman, The Queen Elizabeth Hospital, Woodville, South Australia, Australia; Petr Kolman, Hospital Kyjov, Kyjov, Czech Republic; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing, MI; Chandra P. Belani, Penn State Hershey Cancer Institute, Hershey; Rita Axelrod, Thomas Jefferson University Hospital, Philadelphia, PA; Qin Qin, Jiang Qian, Evelyn M. McKeegan, Viswanath Devanarayan, Mark D. McKee, Justin L. Ricker, and Dawn M. Carlson, AbbVie, North Chicago, IL.
Chandra P BelaniSuresh S. Ramalingam and Taofeek K. Owonikoko, Winship Cancer Institute of Emory University, Atlanta, GA; Mikhail Shtivelband, Ironwood Cancer and Research Centers, Chandler, AZ; Ross A. Soo, National University Cancer Institute, National University Health System, Singapore, Singapore; Carlos H. Barrios, Pontifícia Universidade Católica do Rio Grande do Sul School of Medicine, Porto Alegre; José G.M. Segalla, Hospital Amaral Carvalho, Jau; Jose R. Pereira, Instituto Brasileiro de Cancerologia Toracica, Sao Paulo, Brazil; Anatoly Makhson, Moscow City Oncology Hospital No. 62; Vera A. Gorbunova, N.N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia; Kenneth B. Pittman, The Queen Elizabeth Hospital, Woodville, South Australia, Australia; Petr Kolman, Hospital Kyjov, Kyjov, Czech Republic; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing, MI; Chandra P. Belani, Penn State Hershey Cancer Institute, Hershey; Rita Axelrod, Thomas Jefferson University Hospital, Philadelphia, PA; Qin Qin, Jiang Qian, Evelyn M. McKeegan, Viswanath Devanarayan, Mark D. McKee, Justin L. Ricker, and Dawn M. Carlson, AbbVie, North Chicago, IL.
Rita AxelrodSuresh S. Ramalingam and Taofeek K. Owonikoko, Winship Cancer Institute of Emory University, Atlanta, GA; Mikhail Shtivelband, Ironwood Cancer and Research Centers, Chandler, AZ; Ross A. Soo, National University Cancer Institute, National University Health System, Singapore, Singapore; Carlos H. Barrios, Pontifícia Universidade Católica do Rio Grande do Sul School of Medicine, Porto Alegre; José G.M. Segalla, Hospital Amaral Carvalho, Jau; Jose R. Pereira, Instituto Brasileiro de Cancerologia Toracica, Sao Paulo, Brazil; Anatoly Makhson, Moscow City Oncology Hospital No. 62; Vera A. Gorbunova, N.N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia; Kenneth B. Pittman, The Queen Elizabeth Hospital, Woodville, South Australia, Australia; Petr Kolman, Hospital Kyjov, Kyjov, Czech Republic; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing, MI; Chandra P. Belani, Penn State Hershey Cancer Institute, Hershey; Rita Axelrod, Thomas Jefferson University Hospital, Philadelphia, PA; Qin Qin, Jiang Qian, Evelyn M. McKeegan, Viswanath Devanarayan, Mark D. McKee, Justin L. Ricker, and Dawn M. Carlson, AbbVie, North Chicago, IL.
Taofeek K OwonikokoSuresh S. Ramalingam and Taofeek K. Owonikoko, Winship Cancer Institute of Emory University, Atlanta, GA; Mikhail Shtivelband, Ironwood Cancer and Research Centers, Chandler, AZ; Ross A. Soo, National University Cancer Institute, National University Health System, Singapore, Singapore; Carlos H. Barrios, Pontifícia Universidade Católica do Rio Grande do Sul School of Medicine, Porto Alegre; José G.M. Segalla, Hospital Amaral Carvalho, Jau; Jose R. Pereira, Instituto Brasileiro de Cancerologia Toracica, Sao Paulo, Brazil; Anatoly Makhson, Moscow City Oncology Hospital No. 62; Vera A. Gorbunova, N.N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia; Kenneth B. Pittman, The Queen Elizabeth Hospital, Woodville, South Australia, Australia; Petr Kolman, Hospital Kyjov, Kyjov, Czech Republic; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing, MI; Chandra P. Belani, Penn State Hershey Cancer Institute, Hershey; Rita Axelrod, Thomas Jefferson University Hospital, Philadelphia, PA; Qin Qin, Jiang Qian, Evelyn M. McKeegan, Viswanath Devanarayan, Mark D. McKee, Justin L. Ricker, and Dawn M. Carlson, AbbVie, North Chicago, IL.
Qin QinSuresh S. Ramalingam and Taofeek K. Owonikoko, Winship Cancer Institute of Emory University, Atlanta, GA; Mikhail Shtivelband, Ironwood Cancer and Research Centers, Chandler, AZ; Ross A. Soo, National University Cancer Institute, National University Health System, Singapore, Singapore; Carlos H. Barrios, Pontifícia Universidade Católica do Rio Grande do Sul School of Medicine, Porto Alegre; José G.M. Segalla, Hospital Amaral Carvalho, Jau; Jose R. Pereira, Instituto Brasileiro de Cancerologia Toracica, Sao Paulo, Brazil; Anatoly Makhson, Moscow City Oncology Hospital No. 62; Vera A. Gorbunova, N.N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia; Kenneth B. Pittman, The Queen Elizabeth Hospital, Woodville, South Australia, Australia; Petr Kolman, Hospital Kyjov, Kyjov, Czech Republic; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing, MI; Chandra P. Belani, Penn State Hershey Cancer Institute, Hershey; Rita Axelrod, Thomas Jefferson University Hospital, Philadelphia, PA; Qin Qin, Jiang Qian, Evelyn M. McKeegan, Viswanath Devanarayan, Mark D. McKee, Justin L. Ricker, and Dawn M. Carlson, AbbVie, North Chicago, IL.
Jiang QianSuresh S. Ramalingam and Taofeek K. Owonikoko, Winship Cancer Institute of Emory University, Atlanta, GA; Mikhail Shtivelband, Ironwood Cancer and Research Centers, Chandler, AZ; Ross A. Soo, National University Cancer Institute, National University Health System, Singapore, Singapore; Carlos H. Barrios, Pontifícia Universidade Católica do Rio Grande do Sul School of Medicine, Porto Alegre; José G.M. Segalla, Hospital Amaral Carvalho, Jau; Jose R. Pereira, Instituto Brasileiro de Cancerologia Toracica, Sao Paulo, Brazil; Anatoly Makhson, Moscow City Oncology Hospital No. 62; Vera A. Gorbunova, N.N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia; Kenneth B. Pittman, The Queen Elizabeth Hospital, Woodville, South Australia, Australia; Petr Kolman, Hospital Kyjov, Kyjov, Czech Republic; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing, MI; Chandra P. Belani, Penn State Hershey Cancer Institute, Hershey; Rita Axelrod, Thomas Jefferson University Hospital, Philadelphia, PA; Qin Qin, Jiang Qian, Evelyn M. McKeegan, Viswanath Devanarayan, Mark D. McKee, Justin L. Ricker, and Dawn M. Carlson, AbbVie, North Chicago, IL.
Evelyn M McKeeganSuresh S. Ramalingam and Taofeek K. Owonikoko, Winship Cancer Institute of Emory University, Atlanta, GA; Mikhail Shtivelband, Ironwood Cancer and Research Centers, Chandler, AZ; Ross A. Soo, National University Cancer Institute, National University Health System, Singapore, Singapore; Carlos H. Barrios, Pontifícia Universidade Católica do Rio Grande do Sul School of Medicine, Porto Alegre; José G.M. Segalla, Hospital Amaral Carvalho, Jau; Jose R. Pereira, Instituto Brasileiro de Cancerologia Toracica, Sao Paulo, Brazil; Anatoly Makhson, Moscow City Oncology Hospital No. 62; Vera A. Gorbunova, N.N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia; Kenneth B. Pittman, The Queen Elizabeth Hospital, Woodville, South Australia, Australia; Petr Kolman, Hospital Kyjov, Kyjov, Czech Republic; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing, MI; Chandra P. Belani, Penn State Hershey Cancer Institute, Hershey; Rita Axelrod, Thomas Jefferson University Hospital, Philadelphia, PA; Qin Qin, Jiang Qian, Evelyn M. McKeegan, Viswanath Devanarayan, Mark D. McKee, Justin L. Ricker, and Dawn M. Carlson, AbbVie, North Chicago, IL.
Viswanath DevanarayanSuresh S. Ramalingam and Taofeek K. Owonikoko, Winship Cancer Institute of Emory University, Atlanta, GA; Mikhail Shtivelband, Ironwood Cancer and Research Centers, Chandler, AZ; Ross A. Soo, National University Cancer Institute, National University Health System, Singapore, Singapore; Carlos H. Barrios, Pontifícia Universidade Católica do Rio Grande do Sul School of Medicine, Porto Alegre; José G.M. Segalla, Hospital Amaral Carvalho, Jau; Jose R. Pereira, Instituto Brasileiro de Cancerologia Toracica, Sao Paulo, Brazil; Anatoly Makhson, Moscow City Oncology Hospital No. 62; Vera A. Gorbunova, N.N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia; Kenneth B. Pittman, The Queen Elizabeth Hospital, Woodville, South Australia, Australia; Petr Kolman, Hospital Kyjov, Kyjov, Czech Republic; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing, MI; Chandra P. Belani, Penn State Hershey Cancer Institute, Hershey; Rita Axelrod, Thomas Jefferson University Hospital, Philadelphia, PA; Qin Qin, Jiang Qian, Evelyn M. McKeegan, Viswanath Devanarayan, Mark D. McKee, Justin L. Ricker, and Dawn M. Carlson, AbbVie, North Chicago, IL.
Mark D McKeeSuresh S. Ramalingam and Taofeek K. Owonikoko, Winship Cancer Institute of Emory University, Atlanta, GA; Mikhail Shtivelband, Ironwood Cancer and Research Centers, Chandler, AZ; Ross A. Soo, National University Cancer Institute, National University Health System, Singapore, Singapore; Carlos H. Barrios, Pontifícia Universidade Católica do Rio Grande do Sul School of Medicine, Porto Alegre; José G.M. Segalla, Hospital Amaral Carvalho, Jau; Jose R. Pereira, Instituto Brasileiro de Cancerologia Toracica, Sao Paulo, Brazil; Anatoly Makhson, Moscow City Oncology Hospital No. 62; Vera A. Gorbunova, N.N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia; Kenneth B. Pittman, The Queen Elizabeth Hospital, Woodville, South Australia, Australia; Petr Kolman, Hospital Kyjov, Kyjov, Czech Republic; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing, MI; Chandra P. Belani, Penn State Hershey Cancer Institute, Hershey; Rita Axelrod, Thomas Jefferson University Hospital, Philadelphia, PA; Qin Qin, Jiang Qian, Evelyn M. McKeegan, Viswanath Devanarayan, Mark D. McKee, Justin L. Ricker, and Dawn M. Carlson, AbbVie, North Chicago, IL.
Justin L RickerSuresh S. Ramalingam and Taofeek K. Owonikoko, Winship Cancer Institute of Emory University, Atlanta, GA; Mikhail Shtivelband, Ironwood Cancer and Research Centers, Chandler, AZ; Ross A. Soo, National University Cancer Institute, National University Health System, Singapore, Singapore; Carlos H. Barrios, Pontifícia Universidade Católica do Rio Grande do Sul School of Medicine, Porto Alegre; José G.M. Segalla, Hospital Amaral Carvalho, Jau; Jose R. Pereira, Instituto Brasileiro de Cancerologia Toracica, Sao Paulo, Brazil; Anatoly Makhson, Moscow City Oncology Hospital No. 62; Vera A. Gorbunova, N.N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia; Kenneth B. Pittman, The Queen Elizabeth Hospital, Woodville, South Australia, Australia; Petr Kolman, Hospital Kyjov, Kyjov, Czech Republic; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing, MI; Chandra P. Belani, Penn State Hershey Cancer Institute, Hershey; Rita Axelrod, Thomas Jefferson University Hospital, Philadelphia, PA; Qin Qin, Jiang Qian, Evelyn M. McKeegan, Viswanath Devanarayan, Mark D. McKee, Justin L. Ricker, and Dawn M. Carlson, AbbVie, North Chicago, IL.
Dawn M CarlsonSuresh S. Ramalingam and Taofeek K. Owonikoko, Winship Cancer Institute of Emory University, Atlanta, GA; Mikhail Shtivelband, Ironwood Cancer and Research Centers, Chandler, AZ; Ross A. Soo, National University Cancer Institute, National University Health System, Singapore, Singapore; Carlos H. Barrios, Pontifícia Universidade Católica do Rio Grande do Sul School of Medicine, Porto Alegre; José G.M. Segalla, Hospital Amaral Carvalho, Jau; Jose R. Pereira, Instituto Brasileiro de Cancerologia Toracica, Sao Paulo, Brazil; Anatoly Makhson, Moscow City Oncology Hospital No. 62; Vera A. Gorbunova, N.N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia; Kenneth B. Pittman, The Queen Elizabeth Hospital, Woodville, South Australia, Australia; Petr Kolman, Hospital Kyjov, Kyjov, Czech Republic; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing, MI; Chandra P. Belani, Penn State Hershey Cancer Institute, Hershey; Rita Axelrod, Thomas Jefferson University Hospital, Philadelphia, PA; Qin Qin, Jiang Qian, Evelyn M. McKeegan, Viswanath Devanarayan, Mark D. McKee, Justin L. Ricker, and Dawn M. Carlson, AbbVie, North Chicago, IL.
Vera A GorbunovaSuresh S. Ramalingam and Taofeek K. Owonikoko, Winship Cancer Institute of Emory University, Atlanta, GA; Mikhail Shtivelband, Ironwood Cancer and Research Centers, Chandler, AZ; Ross A. Soo, National University Cancer Institute, National University Health System, Singapore, Singapore; Carlos H. Barrios, Pontifícia Universidade Católica do Rio Grande do Sul School of Medicine, Porto Alegre; José G.M. Segalla, Hospital Amaral Carvalho, Jau; Jose R. Pereira, Instituto Brasileiro de Cancerologia Toracica, Sao Paulo, Brazil; Anatoly Makhson, Moscow City Oncology Hospital No. 62; Vera A. Gorbunova, N.N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia; Kenneth B. Pittman, The Queen Elizabeth Hospital, Woodville, South Australia, Australia; Petr Kolman, Hospital Kyjov, Kyjov, Czech Republic; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing, MI; Chandra P. Belani, Penn State Hershey Cancer Institute, Hershey; Rita Axelrod, Thomas Jefferson University Hospital, Philadelphia, PA; Qin Qin, Jiang Qian, Evelyn M. McKeegan, Viswanath Devanarayan, Mark D. McKee, Justin L. Ricker, and Dawn M. Carlson, AbbVie, North Chicago, IL.
AbbVie (Japan)AbbVie (United States) · US
Funding
Winship Cancer Institute, National Clinical Trials Network Lead Academic ParticipU10CA180864 · NCI · EMORY UNIVERSITY · PI BEITLER, JONATHAN, RAMALINGAM, SURESH S · 2014 to 2018
$2.9MAbstract
purposeLinifanib, a potent, selective inhibitor of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptors, has single-agent activity in non-small-cell lung cancer (NSCLC). We evaluated linifanib with carboplatin and paclitaxel as first-line therapy of advanced nonsquamous NSCLC. PATIENTS AND
methodsPatients with stage IIIB/IV nonsquamous NSCLC were randomly assigned to 3-week cycles of carboplatin (area under the curve 6) and paclitaxel (200 mg/m(2)) with daily placebo (arm A), linifanib 7.5 mg (arm B), or linifanib 12.5 mg (arm C). The primary end point was progression-free survival (PFS); secondary efficacy end points included overall survival (OS) and objective response rate.
resultsOne hundred thirty-eight patients were randomly assigned (median age, 61 years; 57% men; 84% smokers). Median PFS times were 5.4 months (95% CI, 4.2 to 5.7 months) in arm A (n = 47), 8.3 months (95% CI, 4.2 to 10.8 months) in arm B (n = 44), and 7.3 months (95% CI, 4.6 to 10.8 months) in arm C (n = 47). Hazard ratios (HRs) for PFS were 0.51 for arm B versus A (P = .022) and 0.64 for arm C versus A (P = .118). Median OS times were 11.3, 11.4, and 13.0 months in arms A, B, and C, respectively. HRs for OS were 1.08 for arm B versus A (P = .779) and 0.88 for arm C versus A (P = .650). Both linifanib doses were associated with increased toxicity, including a higher incidence of adverse events known to be associated with VEGF/PDGF inhibition. Baseline plasma carcinoembryonic antigen/cytokeratin 19 fragments biomarker signature was associated with PFS improvement and a trend toward OS improvement with linifanib 12.5 mg.
conclusionAddition of linifanib to chemotherapy significantly improved PFS (arm B), with a modest trend for survival benefit (arm C) and increased toxicity reflective of known VEGF/PDGF inhibitory effects.
Indexed as
Administration, OralAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Non-Small-Cell LungDisease-Free SurvivalDrug Administration ScheduleFemaleHumansIndazolesKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedPaclitaxelCarboplatinIndazoleslinifanibPaclitaxelPhenylurea CompoundsReceptors, Platelet-Derived Growth FactorVascular Endothelial Growth Factor AVEGFA protein, human
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.